MPH Share Price Performance
Recent MPH News & Updates
No updates
Medicure Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.17
- Gross Margin
- 56.76%
- Net Profit Margin
- -8.22%
- Debt/Equity Ratio
- 0%
Medicure Inc. Competitors
About MPH
- Founded
- 1997
- Employees
- n/a
- CEO
- WebsiteView website
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.
Canadian Market Performance
- 7 Days: 0.4%
- 3 Months: 10.5%
- 1 Year: 17.4%
- Year to Date: 10.5%
The Information Technology sector gained 3.1% while the market remained flat over the last week. More promisingly, the market is up 17% over the past year. Looking forward, earnings are forecast to grow by 12% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading